Delivery Order SPE2DB24D2101-SPE2DB26FKFEH
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $7,558.78 to AmerisourceBergen Drug Corp for the supply of Erleada 60 mg tablets (120-count units) on September 26, 2025, with an ultimate completion date of October 20, 2025. This firm fixed-price delivery order was competitively awarded without any set-aside designation and represents a child order under AmerisourceBergen's larger pharmaceutical supply contract vehicle. The product will be performed from the contractor's...
- The Defense Logistics Agency awarded a $7,558.78 delivery order to AmerisourceBergen Drug Corp on September 26, 2025, for the supply of Erleada 60 mg tablets (120 count). This firm fixed-price contract, with an ultimate completion date of October 20, 2025, represents a child delivery order under AmerisourceBergen's broader Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at $1 billion through December 2026. The award was competitively made with no set-aside...
- The Defense Logistics Agency awarded a delivery order valued at $7,558.78 to AmerisourceBergen Drug Corp for Erleada 60 mg tablets (120 count) on September 2, 2025, with an ultimate completion date of September 23, 2025. This firm fixed price delivery order represents a non-competitive, non-set-aside award under the company's existing Indefinite Delivery Contract with DLA Troop Support Medical. The contract will be performed at AmerisourceBergen's corporate headquarters in Conshohocken,...
- The Defense Logistics Agency awarded a $7,558.78 delivery order to AmerisourceBergen Drug Corp on July 28, 2025, for the supply of Erleada 60 mg tablets (120 count). This firm fixed price contract, with an ultimate completion date of August 18, 2025, represents a non-set-aside competitive award. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with...
- The Defense Logistics Agency awarded a delivery order valued at $7,558.78 to AmerisourceBergen Drug Corp for the supply of Erleada 60 mg tablets (120 count) on August 19, 2025, with a completion date of September 10, 2025. This firm fixed-price contract is being performed at the contractor's Conshohocken, Pennsylvania location and represents a non-competitive set-aside award. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical vendor for federal medical procurement,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 28, 2025, for the supply of Erleada 60 mg tablets in quantities of 120 units. This competitively awarded, non-set-aside delivery order carries a ceiling value of $29,822.56 and is structured under a firm fixed-price arrangement, with an ultimate completion date of October 20, 2025. The work will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency awarded a delivery order valued at $7,558.78 to AmerisourceBergen Drug Corp for the supply of Erleada 60 mg tablets (120-count units) on August 4, 2025, with completion scheduled for August 25, 2025. This firm fixed-price, non-set-aside contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX and valued at $999,999,999.00 through December 2026. The pharmaceutical product...
- The Defense Logistics Agency awarded a $14,704.98 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Erleada 240 mg tablets (30-count units) with a completion date of September 2, 2025. This non-competitive award represents a child contract issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. The pharmaceutical distributor, headquartered in Conshohocken,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Erleada 60 mg tablets (120-count units) valued at $7,558.78 under a firm fixed-price contract. The award, issued on August 11, 2025, with completion scheduled for September 2, 2025, represents a non-competitive delivery order with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, will fulfill this order from its corporate office location,...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 25, 2025, for the supply of Erleada 240 mg tablets in quantities of 30 units. This contract represents a firm fixed price delivery order with a ceiling value of $7,352.49 and is scheduled for completion by October 17, 2025. The award was made on a competitive basis with no set-aside designation. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as the prime...
- SPE2DB24D2101Indefinite Delivery Contract
- SPE2DB24D2101-SPE2DB26FKFEHDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $7,558.79 to AmerisourceBergen Drug Corp for the supply of Erleada 60 mg tablets (120-count units) on October 29, 2025, with completion scheduled for November 20, 2025. This competitively awarded, firm fixed-price contract has no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and critical federal medical procurement vendor, fulfills this order as a child delivery order under its larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. This delivery order represents a component of AmerisourceBergen's comprehensive pharmaceutical supply portfolio supporting military and veteran healthcare systems. The company's IDC vehicle enables it to supply a diverse range of medications, vaccines, and medical supplies across multiple therapeutic domains to the Defense Health Agency, U.S. Coast Guard, and other federal healthcare systems. The specific provision of Erleada, a specialty pharmaceutical used in oncology treatment, aligns with the company's demonstrated capability in delivering specialized medical commodities through the DLA's global pharmaceutical support framework.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $7.6k | 10/29/25 |